Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Pulmatrix Inc PULM

Healthcare
Pulmatrix, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of novel inhaled therapeutic products intended to prevent and treat respiratory and other diseases with important unmet medical needs using its patented iSPERSE technology. The Company’s proprietary product pipeline includes treatments for central nervous system (CNS) disorders, such as... see more

Recent & Breaking News (NDAQ:PULM)

Pulmatrix Reports 3rd Quarter Results; Provides Update on Business & Development Pipeline

PR Newswire November 12, 2015

Pulmatrix to Webcast Investor Presentation at Upcoming Investor Conferences

PR Newswire October 9, 2015

Study: Pulmatrix's PUR1900 Inhaled Cystic Fibrosis Drug Demonstrates High Lung Retention and Potency Against Fungal Infection

PR Newswire October 8, 2015

NIH Awards $1.7 Million Grant for Celdara Medical and Pulmatrix to Develop an Inhaled Biologic Treatment for Idiopathic Pulmonary Fibrosis

PR Newswire October 1, 2015

Pulmatrix to Report Clinical Data on PUR0200 in Patients with Chronic Obstructive Pulmonary Disease

PR Newswire September 23, 2015

Pulmatrix to Highlight PUR1900 Data at 2015 North American Cystic Fibrosis Conference

PR Newswire September 11, 2015

Pulmatrix to Present at the Rodman & Renshaw Global Investment Conference on September 10, 2015

PR Newswire September 3, 2015

Pulmatrix Issued New Composition of Matter Patent Covering iSPERSE(TM) Technology

PR Newswire September 2, 2015

Pulmatrix Reports 2nd Quarter Results; Provides Update on Business & Development Pipeline

PR Newswire August 14, 2015

Pulmatrix Presentation Now Available for On-Demand Viewing

Canada NewsWire August 12, 2015

Q1 Figures Show Oculus Innovative Sciences Executing Turnaround Plan

Accesswire August 5, 2015

Q1 Figures Show Oculus Innovative Sciences Executing Turnaround Plan

Accesswire August 5, 2015

Nasdaq Companies to Present Online to Investors on August 6

Canada NewsWire August 4, 2015

Nasdaq Companies to Present Online to Investors on August 6

Canada NewsWire August 4, 2015

Nasdaq Companies to Present Online to Investors on August 6

Canada NewsWire August 4, 2015

Nasdaq Companies to Present Online to Investors on August 6

Canada NewsWire August 4, 2015

Nasdaq Companies to Present Online to Investors on August 6

Canada NewsWire August 4, 2015

Nasdaq Companies to Present Online to Investors on August 6

Canada NewsWire August 4, 2015

Nasdaq Companies to Present Online to Investors on August 6

Canada NewsWire August 4, 2015

Nasdaq Companies to Present Online to Investors on August 6

Canada NewsWire August 4, 2015